IL158807A0 - 5-ht receptor ligands and uses thereof - Google Patents

5-ht receptor ligands and uses thereof

Info

Publication number
IL158807A0
IL158807A0 IL15880702A IL15880702A IL158807A0 IL 158807 A0 IL158807 A0 IL 158807A0 IL 15880702 A IL15880702 A IL 15880702A IL 15880702 A IL15880702 A IL 15880702A IL 158807 A0 IL158807 A0 IL 158807A0
Authority
IL
Israel
Prior art keywords
receptor ligands
ligands
receptor
Prior art date
Application number
IL15880702A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL158807A0 publication Critical patent/IL158807A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15880702A 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof IL158807A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29995301P 2001-06-21 2001-06-21
PCT/IB2002/002293 WO2003000666A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
IL158807A0 true IL158807A0 (en) 2004-05-12

Family

ID=23157027

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15880802A IL158808A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof
IL15880702A IL158807A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15880802A IL158808A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Country Status (39)

Country Link
US (6) US6825198B2 (en)
EP (2) EP1401819A1 (en)
JP (2) JP2005501821A (en)
KR (2) KR100566854B1 (en)
CN (2) CN1630645A (en)
AP (1) AP2002002561A0 (en)
AR (1) AR036095A1 (en)
AU (1) AU2002309173B2 (en)
BG (2) BG108491A (en)
BR (2) BR0210503A (en)
CA (2) CA2455292A1 (en)
CR (1) CR7168A (en)
CZ (2) CZ20033508A3 (en)
DO (1) DOP2002000412A (en)
EA (2) EA200301213A1 (en)
EC (2) ECSP034881A (en)
EE (2) EE200400026A (en)
GE (1) GEP20053655B (en)
GT (1) GT200200120A (en)
HR (1) HRP20031042A2 (en)
HU (2) HUP0400251A3 (en)
IL (2) IL158808A0 (en)
IS (2) IS7040A (en)
MA (2) MA27036A1 (en)
MX (2) MXPA03011940A (en)
NO (2) NO20035698L (en)
NZ (1) NZ529542A (en)
OA (2) OA12621A (en)
PA (1) PA8548901A1 (en)
PE (1) PE20030268A1 (en)
PL (2) PL367746A1 (en)
SK (2) SK15712003A3 (en)
SV (1) SV2003001102A (en)
TN (2) TNSN03143A1 (en)
UA (1) UA74443C2 (en)
UY (1) UY27343A1 (en)
WO (2) WO2003000666A1 (en)
YU (1) YU95303A (en)
ZA (2) ZA200308843B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
JP2005504043A (en) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． Peptidomimetics of biologically active metal peptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2004000830A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP5015586B2 (en) * 2003-01-29 2012-08-29 アステランド ユーケイ リミテッド EP4 receptor antagonist
MXPA05009063A (en) 2003-02-26 2005-12-12 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
CL2004000826A1 (en) 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CN101792417A (en) 2003-06-17 2010-08-04 艾尼纳制药公司 Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
AU2004265243A1 (en) * 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c receptor associated diseases
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005033105A2 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP2008501698A (en) * 2004-06-04 2008-01-24 アリーナ ファーマシューティカルズ， インコーポレイテッド Substituted aryl and heteroaryl derivatives as metabolic regulators and their related diseases prevention and treatment
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US8114502B2 (en) * 2004-09-02 2012-02-14 3M Innovative Properties Company Substrates with multiple images
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (en) * 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc TREATMENT OF OBESITY AND RELATED DISEASES
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
AR051946A1 (en) * 2004-11-05 2007-02-21 Wyeth Corp FORMULATIONS OF DERIVATIVES OF [1,4] DIAZEPINA [6,7,1-IJ] QUINOLINA
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006064780A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
KR101281919B1 (en) 2004-12-21 2013-07-03 아레나 파마슈티칼스, 인크. Crystalline forms of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
PT1833473E (en) 2004-12-23 2009-12-17 Arena Pharm Inc 5ht2c receptor modulator compositions and methods of use
EP1856075A1 (en) * 2005-01-25 2007-11-21 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
EP1869000A1 (en) * 2005-03-31 2007-12-26 Pfizer Products Incorporated Cyclopentapyridine and tetrahydroquinoline derivatives
US7594976B2 (en) * 2005-05-13 2009-09-29 3M Innovative Properties Company Methods of manufacturing substrates
KR20080047375A (en) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. Novel pharmaceutical compounds
ES2535854T3 (en) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Substituted Pyrazole Compounds
SI1959955T1 (en) * 2005-12-05 2011-02-28 Pfizer Prod Inc Method of treating abnormal cell growth
RU2387650C2 (en) * 2005-12-05 2010-04-27 Пфайзер Продактс Инк. C-met/hgfr inhibitor polymorphs
JP2009521445A (en) * 2005-12-21 2009-06-04 シェーリング コーポレイション Combination of H3 antagonist / inverse agonist and appetite suppressant
EP2001852A2 (en) 2006-04-03 2008-12-17 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2032554A1 (en) * 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
KR20090029299A (en) * 2006-07-14 2009-03-20 화이자 프로덕츠 인코포레이티드 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CN101583593A (en) 2006-11-13 2009-11-18 辉瑞产品公司 Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
CA2670285A1 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
CA2675638C (en) 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
JP5491421B2 (en) * 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド Process for the preparation of intermediates related to the 5-HT2C agonist (R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN102118969B (en) * 2008-06-12 2017-03-08 詹森药业有限公司 Histamine H4The diamino-pyridine of receptor, di-amino-pyrimidine and diamino radical pyridazine regulator
WO2009154739A2 (en) * 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (en) 2008-10-31 2011-12-07 默沙东公司 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5514831B2 (en) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション Substituted bicyclic amines for the treatment of diabetes
CN102648170A (en) 2009-06-18 2012-08-22 艾尼纳制药公司 Processes for the preparation of 5-HT2C receptor agonists
PL2445899T3 (en) * 2009-06-26 2017-08-31 Sanofi Novel fumarate salts of a histamine h3 receptor antagonist
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutic agent for fibromyalgia
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme Novel prolylcarboxypeptidase inhibitors
EP3613504A1 (en) * 2010-06-23 2020-02-26 Johnson Matthey Public Limited Company Pi-allylpalladium and pi-allylnickel complexes for use as catalysts in carbon-carbon and carbon-nitrogen coupling reactions
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
EP2939677A1 (en) 2010-09-01 2015-11-04 Arena Pharmaceuticals, Inc. Administration of lorcaserin to indviduals with renal impairment
CN103189360A (en) 2010-09-01 2013-07-03 艾尼纳制药公司 Non-hygroscopic salts of 5-HT2C agonists
ES2704455T3 (en) 2010-09-01 2019-03-18 Arena Pharm Inc Pharmaceutical forms of modified release of 5-HT2C agonists useful for weight management
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2678332B1 (en) * 2011-02-25 2016-05-18 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
MX2014014308A (en) * 2012-05-30 2015-02-12 Hoffmann La Roche Pyrrolidino heterocycles.
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
MX2017016530A (en) 2015-06-22 2018-03-12 Arena Pharm Inc Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluo romethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)a cetic acid(compound1) for use in sipi receptor-associated disorders.
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited Therapeutic agent for stress urinary incontinence and fecal incontinence
CA3132731A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
CN111704582B (en) * 2020-06-23 2021-06-11 杭州煌森生物科技有限公司 Preparation method of Favipiravir and derivatives thereof
CN115618396B (en) * 2022-11-28 2023-04-07 云账户技术(天津)有限公司 Data encryption method and device

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (en) 1963-11-19
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
GB1165283A (en) * 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
FR2281117A2 (en) 1974-08-09 1976-03-05 Ugine Kuhlmann NEW PIPERAZINO-PYRIMIDINES FOR USE AS MEDICINAL PRODUCTS
US4166852A (en) 1974-08-09 1979-09-04 Produits Chimiques Ugine Kuhlmann Piperazino-pyrimidines and their use as spasmolytic agents
US4081542A (en) 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
SE421695B (en) * 1975-04-21 1982-01-25 Merck & Co Inc SET TO MAKE PIPERAZINYL PYRAZINES
FR2311776A1 (en) 1975-05-23 1976-12-17 Sogeras 2,4-DIAMINO-5-CHLORO-6 PYRIMIDINES AND PROCESS FOR THEIR PREPARATION
FI70411C (en) 1980-12-29 1986-09-19 Pfizer FORM OF ANTHYPERTENSIVE 4-AMINO-6,7-DIMETOXY-2-PIPERAZINOQUINAZOLE DERIVATIVES
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
DE3905364A1 (en) 1989-02-22 1990-08-23 Hoechst Ag SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A TOOL
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
JPH0665203A (en) 1992-06-25 1994-03-08 Elf Sanofi Heterocyclic derivative of piperazine
KR950703539A (en) 1992-09-28 1995-09-20 알렌 제이. 스피겔 SUBSTITUTED PYRIMIDINES FOR CONTROL OR DIABETIC COMPLICATIONS
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5419301A (en) * 1994-04-14 1995-05-30 Ford Motor Company Adaptive control of camless valvetrain
CA2217034A1 (en) * 1995-04-03 1996-10-10 Sumitomo Pharmaceuticals Company, Limited Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DE69711965T2 (en) 1996-02-29 2003-01-23 Pfizer Inc., New York Use of sorbitol dehydrogenase inhibitors to reduce ischemia-associated tissue damage
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
KR100239800B1 (en) * 1996-11-28 2000-03-02 손경식 4,5-diaminopyrimidine derivatives and its preparation
DE19710435A1 (en) 1997-03-13 1998-09-17 Hoechst Ag Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
DE60024986T2 (en) 1999-05-21 2006-07-27 Biovitrum Ab PYRAZINYL-PIPERAZINE COMPOUNDS, THEIR USE AND MANUFACTURE
SE0002754D0 (en) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (en) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
CA2428905A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
JP4387103B2 (en) * 2000-11-20 2009-12-16 ビオヴィトルム・アクチボラゲット（プブリクト） Piperazinyl pyrazine compounds as agonists or antagonists of serotonin 5HT-2 receptor

Also Published As

Publication number Publication date
JP2005501821A (en) 2005-01-20
US6894050B2 (en) 2005-05-17
CZ20033508A3 (en) 2004-05-12
BG108491A (en) 2005-01-31
PA8548901A1 (en) 2003-02-14
EE200400026A (en) 2004-06-15
IL158808A0 (en) 2004-05-12
HUP0400249A2 (en) 2004-08-30
HUP0400251A2 (en) 2004-08-30
SK15712003A3 (en) 2004-06-08
CN1630645A (en) 2005-06-22
IS7040A (en) 2003-11-17
US20030105106A1 (en) 2003-06-05
WO2003000666A1 (en) 2003-01-03
GT200200120A (en) 2003-02-13
MXPA03011941A (en) 2004-03-26
CR7168A (en) 2004-02-23
EA007183B1 (en) 2006-08-25
BR0210503A (en) 2004-05-18
OA12629A (en) 2006-06-14
PE20030268A1 (en) 2003-03-19
KR100566854B1 (en) 2006-04-03
PL367777A1 (en) 2005-03-07
HUP0400251A3 (en) 2006-02-28
AR036095A1 (en) 2004-08-11
AU2002309173B2 (en) 2007-04-26
MA27035A1 (en) 2004-12-20
EP1401820A1 (en) 2004-03-31
OA12621A (en) 2006-06-12
AP2002002561A0 (en) 2002-06-30
TNSN03142A1 (en) 2005-12-23
EA200301213A1 (en) 2004-06-24
MA27036A1 (en) 2004-12-20
UY27343A1 (en) 2003-02-28
BR0210471A (en) 2004-08-10
NO20035697D0 (en) 2003-12-19
CA2450491A1 (en) 2003-01-03
US6995159B2 (en) 2006-02-07
ECSP034884A (en) 2004-01-28
US6825198B2 (en) 2004-11-30
ZA200308842B (en) 2004-11-23
IS7041A (en) 2003-11-17
US20050090503A1 (en) 2005-04-28
CZ20033431A3 (en) 2004-07-14
JP2004534823A (en) 2004-11-18
US20030125334A1 (en) 2003-07-03
ECSP034881A (en) 2004-01-28
WO2003000663A1 (en) 2003-01-03
EE200400025A (en) 2004-06-15
EA200301215A1 (en) 2004-04-29
SV2003001102A (en) 2003-03-18
CA2455292A1 (en) 2003-01-03
DOP2002000412A (en) 2002-12-30
HUP0400249A3 (en) 2009-01-28
PL367746A1 (en) 2005-03-07
YU95303A (en) 2006-08-17
US20050054656A1 (en) 2005-03-10
NO20035698D0 (en) 2003-12-19
UA74443C2 (en) 2005-12-15
NO20035698L (en) 2004-02-17
CN1745074A (en) 2006-03-08
NZ529542A (en) 2005-05-27
TNSN03143A1 (en) 2005-12-23
ZA200308843B (en) 2004-11-23
US20050020604A1 (en) 2005-01-27
HRP20031042A2 (en) 2005-10-31
US20050032809A1 (en) 2005-02-10
EP1401819A1 (en) 2004-03-31
KR20040010767A (en) 2004-01-31
KR20040010765A (en) 2004-01-31
MXPA03011940A (en) 2004-03-26
BG108495A (en) 2004-08-31
SK15672003A3 (en) 2004-05-04
GEP20053655B (en) 2005-11-10

Similar Documents

Publication Publication Date Title
IL158807A0 (en) 5-ht receptor ligands and uses thereof
ZA200507350B (en) Cannabinoid receptor ligands and uses thereof
IL172026A0 (en) Cannabinoid receptor ligands and uses thereof
IL161439A0 (en) Cannabinoid receptor ligands
IL156829A0 (en) Cannabinoid receptor ligands
EP1393657A4 (en) Seat
GB0214835D0 (en) Suspended seat
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
PL354799A1 (en) Complex containing ocif and polysaccharide
AU2002346507A8 (en) Benzazepine derivatives and their use as 5-ht ligands
GB0106434D0 (en) Novel estrogwen receptor ligands and methods II
GB2378645B (en) Seat
GB0100163D0 (en) Novel estrogen receptor ligands and methods
GB0124346D0 (en) Receptor and its use
GB0110662D0 (en) Receptor
GB0125183D0 (en) Receptor
GB0114929D0 (en) Receptor
GB0111959D0 (en) Receptor
GB0128161D0 (en) Receptor protein
AU146542S (en) Hanging seat
GB0211205D0 (en) Receptor and ligand
GB2378644B (en) Seat
GB0211204D0 (en) Receptor and its ligand
CA96919S (en) Spout
GB2371220B (en) Hanger